general news

CNPharm publishes research results of new oral treatment for COVID-19

CNPharm publishes research results of new oral treatment for COVID-19

South Korea-based Hyundai Bioscience has reportedly announced that CNPharm, the company’s major shareholding bio tech firm, has recently published an article in a special issue of journal ‘Pharmaceuticals’. The article contained the research results of CP-COV03, which is a Niclosamide-based oral treatment for SARS-CoV-2.

The treatment is based on the company’s proprietary oral formulation technology, cite sources privy to the matter.

As per reports, CP-COV03’s active pharmaceutical ingredient (the API) inhibits viral replication similar to other game changer antiviral drug candidates. The ingredient also eliminates and degrades the virus within the cell as well as prevents the damage that is caused to lungs due to coronavirus.

These additional mechanisms were lately reported by articles published in the journal ‘Nature’, which suggests that Niclosamide is a promising SARS-CoV-2 drug candidate.

The article published in the ‘Pharmaceuticals’ unveils CNPharma’s in vivo study, where the company administered a single dose of CP-COV03 to rats. The result was that the maximum concentration of the drug in blood (Cmax) was nearly 300 times the level of IC50, while maintaining the level of drug concentration at or above 50% viral inhibition (IC50) for a period of 24 hours.

For the record, CP-COV03 has gained global recognition to be a candidate for a ‘game-changing’ treatment for COVID-19. The candidate is expected to offer robust competition to oral antiviral COVID-19 drugs that are being developed by Roche, Pfizer, and Merck, or Tamiflu, an oral drug that was developed for the H1N1 pandemic.

However, it is to be noted that in the absence of cutting-edge biotechnology, it is nearly not possible to maintain the concentration of Niclosamide in blood at or above the level of IC50 level for a period of 24 hours by means of a single dose.

So far, no such success case has been reported, with only an exception of a nasal inhalation formulation case which is undergoing clinical trials at the University of Cambridge. However, the case achieved IC50 for a 24-hour-period only in the lung tissue.

Source credit:

About the author

Nandita Bhardwaj

Nandita holds a management degree with specialization in marketing, and boasts of a short-term experience in the field of recruitment. Following her passion for writing however, she decided to pursue a career in the field of content development. Presently, Nandita pens down news pieces for, spanning the verticals of business, finance, and technology.